The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
From 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
Experimental — accuracy not yet measuredIn the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Sorted by citations
Items 301–400 of 1,004
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 56
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 55
Milionis, H. J., Ntaios, G., Korompoki, E., Vemmos, K. N., & Michel, P. (2019) · International Journal of Stroke · doi:10.1177/1747493019873594 · Cited by 57
A review of PCSK9 inhibition and its effects beyond LDL receptors
Dixon, D. L., Trankle, C., Buckley, L., Parod, E., Carbone, S., Van Tassell, B. W., & Abbate, A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.07.004 · Cited by 53
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Villa, G., Löthgren, M., Kutikova, L., Lindgren, P., Gandra, S. R., Fonarow, G. C., Sorio, F., Masana, L., Bayés‐Genís, A., & van Hout, B. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.02.011 · Cited by 53
Brouwers, M. C. G. J., Simons, N., Stehouwer, C. D. A., Koek, G. H., Schaper, N. C., & Isaacs, A. J. (2019) · Hepatology Communications · doi:10.1002/hep4.1319 · Cited by 53
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 58
Evaluating bempedoic acid for the treatment of hyperlipidaemia
Penson, P. E., McGowan, M. P., & Banach, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280458 · Cited by 52
Evison, B. J., Palmer, J. T., Lambert, G. C., Treutlein, H., Zeng, J., Nativel, B., Chemello, K., Zhu, Q. X., Wang, J., Teng, Y., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115344 · Cited by 54
Saeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51
Self-citationThe PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
Seidah, N. G. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.2 · Cited by 53
Managing risks in drug discovery: reproducibility of published findings
Kannt, A., & Wieland, T. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1216-8 · Cited by 53
Li, J., Li, S., Zhang, Y., Xu, R., Guo, Y., Zhu, C., Wu, N., Qing, P., Gao, Y., Sun, J., et al. (2015) · Medicine · doi:10.1097/md.0000000000002426 · Cited by 52
Dyslipidaemia in the Middle East: Current status and a call for action
Al‐Rasadi, K., Almahmeed, W. A., AlHabib, K. F., Abifadel, M., Farhan, H. A., Alsifri, S. N., Jambart, S., Zubaid, M., Awan, Z. A., Al-Waili, K., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.925 · Cited by 55
Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.517 · Cited by 51
Janik, M. J., Urbach, D. V., van Nieuwenhuizen, E., Zhao, J., Yellin, O., Baccara-Dinet, M. T., Pordy, R., & Manvelian, G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.913 · Cited by 51
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52
PCSK9 inhibitors in the prevention of cardiovascular disease
Latimer, J., Batty, J. A., Neely, R. D. G., & Kunadian, V. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1364-1 · Cited by 50
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 52
Accuracy of low-density lipoprotein cholesterol estimation at very low levels
Quispe, R., Hendrani, A. D., Elshazly, M. B., Michos, E. D., McEvoy, J. W., Blaha, M. J., Banach, M., Kulkarni, K. R., Toth, P. P., Coresh, J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0852-2 · Cited by 50
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala, R., Gupta, M., Devanabanda, A. R., Bandyopadhyay, D., Aronow, W. S., Ray, K. K., Mamas, M. A., & Ghosh, R. K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2059559 · Cited by 51
Dyslipidemia management update
Chang, Y., & Robidoux, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.005 · Cited by 50
Patti, G., Spinoni, E. G., Grisafi, L., Mehran, R., & Mennuni, M. G. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac049 · Cited by 52
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Banerjee, Y., Santos, R. D., Al‐Rasadi, K., & Rizzo, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.018 · Cited by 49
Kohli, P., Ganz, P., Ma, Y., Scherzer, R., Hur, S., Weigel, B., Grünfeld, C., Deeks, S. G., Wasserman, S. M., Scott, R. C., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002683 · Cited by 51
Self-citationPCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Mannarino, M. R., Sahebkar, A., Bianconi, V., Șerban, M.-C., Banach, M., & Pirro, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.012 · Cited by 49
Vaccination against atherosclerosis
Kobiyama, K., Saigusa, R., & Ley, K. F. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.008 · Cited by 48
Mandraffino, G., Scicali, R., Rodríguez‐Carrio, J., Savarino, F., Mamone, F., Scuruchi, M., Cinquegrani, M., Imbalzano, E., Pino, A. D., Piro, S., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.015 · Cited by 50
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates
Reynolds, V. W., Chinn, M. E., Jolly, J. A., Kelley, T. N., Peter, M. E., Choi, L., Nwosu, S., Leon, B. G. C., & Zuckerman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.003 · Cited by 47
Hong-mei, G., & Zhang, D. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150067 · Cited by 46
Yadav, K., Sharma, M., & Ferdinand, K. C. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.006 · Cited by 48
Afshar, M. S., Kamstrup, P. R., Williams, K., Sniderman, A. D., Nordestgaard, B. G., & Thanassoulis, G. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308271 · Cited by 50
PCSK9 regulates the chemokine receptor CCR2 on monocytes
Grune, J., Meýborg, H., Bezhaeva, T., Kappert, K., Hillmeister, P., Kintscher, U., Pieske, B. M., & Stawowy, P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.085 · Cited by 53
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 49
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84732 · Cited by 46
PCSK9: A emerging participant in heart failure
Xu, Q., Zhao, Y.-M., He, N.-Q., Gao, R., Xu, W., Zhuo, X.-J., Ren, Z., Wu, C., & Liu, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114106 · Cited by 47
Emami, H., Takx, R. A. P., Mayrhofer, T., Janjua, S., Park, J., Pursnani, A. K., Tawakol, A. A., Lu, M. T., Ferencik, M., & Hoffmann, U. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.10.022 · Cited by 45
Taranto, M. D. D., Benito‐Vicente, A., Giacobbe, C., Uribe, K. B., Rubba, P., Etxebarria, A., Guardamagna, O., Gentile, M., Martín, C., & Fortunato, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-15543-x · Cited by 49
Feng, Q., Wei, W., Chung, C. P., Levinson, R. T., Sundermann, A. C., Mosley, J. D., Bastarache, L. A., Ferguson, J. F., Cox, N. J., Roden, D. M., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002642 · Cited by 44
Singh, G., Hussain, Y., Xu, Z., Sholle, E., Michalak, K., Dolan, K., Lee, B. C., van Rosendael, A. R., Fatima, Z., Peña, J. M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239934 · Cited by 46
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Mefford, M. T., Rosenson, R. S., Cushman, M., Farkouh, M. E., McClure, L. A., Wadley, V. G., Irvin, M. R., Bittner, V., Safford, M. M., Somaratne, R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029785 · Cited by 44
Self-citationȘerban, M.-C., Banach, M., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118055 · Cited by 43
Ray, K. K., Dhalwani, N. N., Sibartie, M., Bridges, I. M., Ebenbichler, C. F., Filardi, P. P., Villa, G., Vogt, A., & Bruckert, É. (2022) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcac009 · Cited by 45
Rosei, E. A., & Salvetti, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0155-2 · Cited by 48
New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
Scicali, R., Pino, A. D., Ferrara, V., Urbano, F., Piro, S., Rabuazzo, A. M., & Purrello, F. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1089-4 · Cited by 44
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kašner, M., Hassanein, A., Friebel, J., & Rauch‐Kröhnert, U. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 47
di Mauro, G., Zinzi, A., Scavone, C., Mascolo, A., Gaio, M., Sportiello, L., Ferrajolo, C., Rafaniello, C., Rossi, F., & Capuano, A. (2020) · Drug Safety · doi:10.1007/s40264-020-01021-3 · Cited by 47
CARDIOVASCULAR DISEASE, SIGNALING, GENE/CELL THERAPY AND ADVANCED NANOBIOMATERIALS
Erdil, N. (2024) · Advances in Biology & Earth Sciences · doi:10.62476/abes9s58 · Cited by 44
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J. P., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 45
New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications
Seidah, N. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000295 · Cited by 43
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 44
PCSK9: from biology to clinical applications
Blanchard, V., Khantalin, I., Ramin‐Mangata, S., Chemello, K., Nativel, B., & Lambert, G. C. (2018) · Pathology · doi:10.1016/j.pathol.2018.10.012 · Cited by 47
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 46
Casula, M., Olmastroni, E., Boccalari, M. T., Tragni, E., Pirillo, A., & Catapano, A. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.021 · Cited by 44
Lysosomal acid lipase deficiency – early diagnosis is the key
Strebinger, G., Müller, E., Feldman, A., & Aigner, E. S. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s201630 · Cited by 45
Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Zarić, B. L., Obradovic, M. M., Trpković, A., Banach, M., Mikhailidis, D. P., & Isenović, E. R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190903112146 · Cited by 45
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Gouni‐Berthold, I., Descamps, O. S., Fraass, U., Hartfield, E., Allcott, K., Dent, R. E., & März, W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13066 · Cited by 41
Sattar, N. A., Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. M., & Preiss, D. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.047 · Cited by 40
Self-citationEffects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Filippatos, T. D., Kei, A. A., Rizos, C. V., & Elisaf, M. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417724868 · Cited by 46
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 43
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
PCSK9 inhibitors – past, present and future
Reiner, Ž. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1075506 · Cited by 41
Secondary prevention after coronary artery bypass graft surgery
Kulik, A. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000331 · Cited by 40
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8611-x · Cited by 40
Self-citationApoB in clinical care: Pro and Con
Sniderman, A. D., & Robinson, J. G. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.001 · Cited by 41
Self-citationPre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
Momtazi‐Borojeni, A. A., Jaafari, M. R., Banach, M., Gorabi, A. M., Sahraei, H., & Sahebkar, A. (2021) · Vaccines · doi:10.3390/vaccines9070749 · Cited by 43
Su, J., Xu, J., Yang, J., Yu, Q., Yang, S., Zhang, J., Yao, Q. Z., Zhu, Y., Luo, Y., Ji, L., et al. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0114-2 · Cited by 40
McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis
Paraskevas, K. I., Brown, M. M., Lal, B. K., Myrcha, P., Lyden, S. P., Schneider, P. A., Poredoš, P., Mikhailidis, D. P., Secemsky, E. A., Musiałek, P., et al. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.11.004 · Cited by 39
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Lambert, G. C., Thedrez, A., Croyal, M., Ramin‐Mangata, S., Couret, D., Diotel, N., Nobécourt, E., Krempf, M., LeBail, J. C., Poirier, B., et al. (2017) · Clinical Science · doi:10.1042/cs20160403 · Cited by 41
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Zheng-Lin, B., & Ortíz, A. (2018) · Drugs · doi:10.1007/s40265-017-0858-2 · Cited by 40
Selker, H. P., Eichler, H., Stockbridge, N., McElwee, N. E., Dere, W. H., Cohen, T., Erban, J. K., Seyfert‐Margolis, V., Honig, P. K., Kaitin, K. I., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1347 · Cited by 43
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
Azari, S., Rezapour, A., Omidi, N., Alipour, V., Behzadifar, M., Safari, H., Tajdini, M., & Bragazzi, N. L. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09874-2 · Cited by 42
Mukaz, D. K., Zakai, N. A., Cruz‐Flores, S., McCullough, L. D., & Cushman, M. (2020) · Stroke · doi:10.1161/strokeaha.120.030425 · Cited by 42
Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source
Tatuene, J. K., Nomani, A. Z., Falcione, S. R., Munsterman, D., Sykes, G. P., Joy, T., Spronk, E., Vargas, M. I., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.719329 · Cited by 41
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Yu, M., Tsai, S., & Kuo, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061260 · Cited by 39
PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway
Liu, L.-S., Bai, X.-Q., Gao, Y., Wu, Q., Ren, Z., Li, Q., Pan, L.-H., He, N.-Y., Peng, J., & Tang, Z.-H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161136 · Cited by 38
Kosmas, C. E., DeJesus, E., Morcelo, R., Garcia, F., Montan, P. D., & Guzman, E. (2017) · Drugs in Context · doi:10.7573/dic.212511 · Cited by 39
Cammisotto, V., Baratta, F., Simeone, P., Barale, C., Lupia, E., Galardo, G., Santilli, F., Russo, I., & Pignatelli, P. (2022) · Antioxidants · doi:10.3390/antiox11030569 · Cited by 40
The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress
Bale, B. F., Doneen, A. L., Leimgruber, P. P., & Vigerust, D. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1042729 · Cited by 39
Abtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Reid, C. M., Baumgärtner, I., Wu, D., Hanson, M. E., Hannachi, H., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22721 · Cited by 40
Choi, H., Hwang, J., Nam, T. G., Kim, S. H., Min, D., Park, S. W., & Chung, M. (2017) · Food & Function · doi:10.1039/c7fo00562h · Cited by 38
Ljungberg, J., Holmgren, A., Bergdahl, I. A., Hultdin, J., Norberg, M., Näslund, U., Johansson, B. H., & Söderberg, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007160 · Cited by 39
Hippe, D. S., Phan, B. A. P., Sun, J., Isquith, D. A., O’Brien, K. D., Crouse, J. R., Anderson, T. J., Huston, J., Marcovina, S. M., Hatsukami, T. S., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310368 · Cited by 40
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry
Brunham, L. R., Ruel, I. L., Khoury, É., Hegele, R. A., Couture, P., Bergeron, J., Baass, A. W., Dufour, R., Francis, G. A., Cermakova, L., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.040 · Cited by 41
Stigmasterol accumulation causes cardiac injury and promotes mortality
Tao, C., Shkumatov, A. A., Alexander, S. T., Ason, B. L., & Zhou, M. (2019) · Communications Biology · doi:10.1038/s42003-018-0245-x · Cited by 38
Dyslipidemia and cardiovascular health in childhood nephrotic syndrome
Hari, P., Khandelwal, P., & Smoyer, W. E. (2019) · Pediatric Nephrology · doi:10.1007/s00467-019-04301-y · Cited by 44
Bae, K.-H., Kim, S. W., Choi, Y., Seo, J. B., Kim, N., Kim, C., Lee, W. K., Lee, S., Kim, J. G., Lee, I., et al. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0081 · Cited by 41
PCSK9 Inhibitors and Cardiovascular Events
Sabatine, M. S., Wasserman, S. M., & Stein, E. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508222 · Cited by 39
Self-citationPCSK9 Inhibition to Reduce Cardiovascular Events
Dullaart, R. P. F. (2017) · New England Journal of Medicine · doi:10.1056/nejme1703138 · Cited by 37
Tănase, D. M., Valasciuc, E., Gosav, E. M., Floria, M., Costea, C. F., Dima, N., Tudorancea, I., Maranducă, M. A., & Șerban, I. L. (2022) · Cells · doi:10.3390/cells11172663 · Cited by 38
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 37
Obesity-Related Asthma: Immune Regulation and Potential Targeted Therapies
Yuan, Y., Ran, N., Xiong, L., Wang, G., Guan, X., Wang, Z., Guo, Y., Pang, Z., Fang, K., Lu, J., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/1943497 · Cited by 39
Ascaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.002 · Cited by 48
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
